Effect of Connective Tissue Massage on Premenstrual Syndrome

ConditionPremenstrual Syndrome

Trial statusNot yet recruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexFemale

Age17-25

SponsorCairo University

About this trial

This study will be conducted to investigate the effect of connective tissue massage on premenstrual syndrome.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Virgin adolescent females diagnosed with premenstrual syndrome.

Their age will be ranged from 17-25 years (3 years post puberty).

Their body mass index (BMI) will be less than 30 kg/m2 .

All are of regular menstrual cycles.

Disqualifiers

Any pathological finding in the pelvic cavity as polycystic ovarian syndrome, endometriosis, and pelvic inflammatory diseases.

Irregular menstruation.

Any history of gynecological intervention.

Open wounds, weak/broken bones or fractures.

Trial design

Design model

Parallel

Treatments tested in this trial

Multivitamins
Drug
All participants will receive multivitamins (vitatron) capsule once daily, for 12 weeks.
Connective tissue massage
Other intervention
Connective tissue massage will be applied on (Sacral, lumbar, last thoracic vertebrae-T12, and subcostal regions), 2 sessions/week for 20 minutes each session for 12 weeks. Treatment will begin 3 days before menstruation to the 4th day of menstruation for 3 successive menstrual cycles.

Treatment groups

50 Participants

are divided into 2 treatment groups

Group A: Multivitamins groupActive comparator 1 intervention

Group B: Connective tissue massage groupExperimental treatment 2 interventions

Trial outcomes

Primary outcomes

Pain intensity

Degrees of menstrual pain will be assessed using a VAS for all participants before and after treatment, which is a method of representing pain on a 10 cm linear scale. A score of zero means "No pain" and 10 means "a very high degree of pain".

Time frame

3 months

Premenstrual syndrome severity

Severity of premenstrual symptoms will be assessed by using the Menstrual Distress Questionnaire (MDQ). Each participant will examine symptom categories (pain, concentration, water retention, behavior changes, negative effect, autonomic reaction, arousal and control) Participants are asked to report the symptoms experienced during their most recent menstrual period, using a rating scale. Responses ranged from (0) No experience of the symptom, (1) mild, (2) moderate, (3) severe and (4) very severe disabling symptoms. Overall scores are interpreted as follows: \>50- mild, 50 to 70- moderate and \>70 severe

Time frame

3 months

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Cairo University

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: